Last reviewed · How we verify
Combogesic® tablets
Combogesic combines paracetamol and ibuprofen to provide analgesic and anti-inflammatory pain relief through dual inhibition of prostaglandin synthesis and central pain pathways.
Combogesic combines paracetamol and ibuprofen to provide analgesic and anti-inflammatory pain relief through dual inhibition of prostaglandin synthesis and central pain pathways. Used for Acute pain management, Postoperative pain.
At a glance
| Generic name | Combogesic® tablets |
|---|---|
| Also known as | Acetaminophen 325 mg and ibuprofen 97.5 mg |
| Sponsor | AFT Pharmaceuticals, Ltd. |
| Drug class | Fixed-dose combination analgesic/NSAID |
| Target | COX-1, COX-2 (ibuprofen); central pain pathways (paracetamol) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
The combination leverages paracetamol's central analgesic and antipyretic effects alongside ibuprofen's peripheral anti-inflammatory action via COX inhibition. This dual mechanism allows for enhanced pain relief at lower individual doses, potentially reducing adverse effects compared to higher single-agent dosing while providing complementary therapeutic benefits for inflammatory pain conditions.
Approved indications
- Acute pain management
- Postoperative pain
Common side effects
- Gastrointestinal upset
- Nausea
- Dyspepsia
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combogesic® tablets CI brief — competitive landscape report
- Combogesic® tablets updates RSS · CI watch RSS
- AFT Pharmaceuticals, Ltd. portfolio CI